**Reviewer’s Comments**

****

**Glaucoma: silent thief of vision - a review**

**Abstract-**

Glaucoma is defined as an optic neuropathy, characterizedfor loss of visual field and injury of the optic nerve. However the mechanism leading to the disease is still unclear. Factors that are responsible for it include glutamate-induced neurotoxicity, nitric oxid based damage, disruption of neurotrophic factor transport and immune-induced neuro destruction.

At present treatment options primarily aim at decreasing intra-ocular pressure (IOP) by utilizing pharmacological agents, laser therapy and surgery. Gaining a better understanding of the pathogenesis can aid in the development of new treatment options and, perhaps, even a cure for glaucoma. This article discusses the pathophysiology ofglaucoma, its detection, diagnosis monitoring and treatment.

**Keywords-** Glaucma, neuropathy, glutamate-induced neurotoxicity, intra-ocular pressure.

**Introduction-**

The glaucoma is defined, currently, as an optic neuro­pathy,characterized for loss of visual field and injury of the optic nerve, being the increase of the intra-ocular pressure (IOP) considered as a risk factor. In glaucoma, the eye’s drainage system becomes clogged so the intraocular fluid cannot drain1. As the fluid builds up, it causes pressure to

build inside the eye. High pressure damages the sensitive optic nerve and results in vision loss2.

Glaucoma is not a single clinical entity but a group of ocular diseases with various causes that ultimately are associated with a progressive optic neuropathy leading to loss of vision.

At present 8.4 million persons worldwide are bilaterally blind as a result of glaucoma (4,472.083 open angle glaucoma (OAG) & 3,936,241 angle closure glaucoma (ACG). Glaucoma is the second worldwide cause of blindness, making it the second leading cause ofbilateral blindness. Glaucoma is termed as “silent thief of sight”, the blindness caused by this disease is irreversible.

Glaucoma affects people of all ages, from babies to older adults3. Although everyone is at risk for glaucoma, those at higher risk include people over age 60, relatives of people with glaucoma, people of African descent, people with diabetes, people with extensive use of steroids, and people who have elevated eye pressure4.

Sight loss resulting from glaucoma cannot be reversed. However, early detection and careful, lifelong treatment with medication or surgery can maintain vision5.

In the most common form of glaucoma, buildup of fluid pressure happens very slowly. Often, there are no uncomfortable or painful symptoms and can suddenlyresult in vision loss.

**Structure of the Eye ball6, 7, 8, 9**

The eye is our organ of sight. It is not shaped like a perfect sphere, composed of the anterior segment and the posterior segment. The anterior segment is made up of the cornea, iris and lens.

**Cornea:** The cornea is transparent and more curved, and is linked to the larger posterior segment, composed of the vitreous, retina, choroid and the outer white shell called the sclera, clear front window of the eye that transmits and focuses light into the eye. The cornea is typically about 11.5 mm (0.3 in) in diameter, and 1/2 mm (500 um) inthickness near its center.



**Normal eye anatomy**

**Iris:** colored part of the eye that helps regulate the amount oflight that enters. The iris is the pigmented circular structure concentrically surrounding the center of the eye, the pupil, which appears to be black. The iris of the eye functions like the diaphragm of a camera, controlling the amount of light reaching the back of the eye by automaticallyadjusting the size of the pupil

**Pupil:** dark aperture in the iris that determines how much light is let into the eye. The size of the pupil, which controls the amount of light entering the eye, is adjusted by the iris' dilator and sphincter muscles. After passing through the cornea, light travelsthrough the pupil (the black dot in the middle of the eye).

**Lens:** transparent structure inside the eye that focuses light rays ontothe retina. Behind the iris sits the lens. By changing its shape, the lens focuses light onto the retina. Through the action of small muscles (called the ciliary muscles), the lens becomes thicker to focus on nearby objects and thinner to focus on distant objects.

**Retina:** nerve layer that lines the back of the eye, senses light, and creates electrical impulses that travel through the optic nerve to the brain. The retina contains the cells that sense light (photoreceptors) and the blood vessels that nourish them.

 **Macula:** The most sensitive part of the retina is a small area called the macula, which has millions of tightly packed photoreceptors (the type called cones). Thehigh density of cones in the macula makes the visual image detailed, just as a high-resolution digital camera has more megapixels.

**Optic nerve:** connects the eye to the brain and carries theelectrical impulses formed by the retina

to the visual cortex of the brain. The photoreceptors in the retina convert the image into electrical signals, which are carried to the brain by the optic nerve.

 Each photoreceptor is linked to a nerve fiber. The nerve fibers from the photoreceptors are bundled together to form the optic nerve. The optic disk, thefirst part of the optic nerve, is at the back of the eye.

There are two main types of photoreceptors: cones and rods.

**i). Cones** are responsible for sharp, detailed central vision and color vision and are clustered mainly in the macula.

**ii). Rods** are responsible for night and peripheral (side) vision. Rodsare more numerous than cones and much more sensitive to light, but they do not register color or contribute to detailed central vision as the cones do. Rods are grouped mainly in the peripheral areas of the retina.

**Vitreous:** clear, jelly-like substance that fills the middle of the eye

**Types of Glaucoma10, 11, 12, 13, 14**

Glaucoma can be classified according to anterior chamber angle findingsand the presence or absence of disease (states) causing elevated IOP and accompanying factors. Different types of glaucoma are identified, that is generally classified into open angle or angle closure glaucoma based on the width of the angle between the cornea and the iris.

**Open-Angle Glaucoma**

Open-angle glaucoma, the most common form of glaucoma, accountingfor at least 90% of all glaucoma cases: is caused by the slow clogging of the drainage canals, resulting in increased eye

pressure has a wide and open angle between the iris and cornea develops slowly and is a lifelong condition has symptoms and damage that are not noticed.

There are no early warning signs of open-angle glaucoma (also called primary or chronic glaucoma). It develops slowly and sometimes without noticeable sight loss for many years. Most people who have open-angle glaucoma feel fine and do not notice a change in their vision. That is why regular eye exams are so important. With early detection, open-angle glaucoma usually responds well to medication. However, it will be very important that you carefully follow your medication regimen to continually preserve healthy eye pressure and prevent vision loss.

**Angle- Closure Glaucoma**

The other main type of glaucoma is called angle-closure glaucoma. It is alsocalled acute glaucoma or narrow-angle glaucoma. This type is rare and: is caused by blocked drainage canals, resulting in a sudden rise in intraocular pressure has a closed or narrow angle between the iris and cornea develops very quickly has symptoms and damage that are usually very noticeable demands immediate medical attention. The closed angle prevents fluid from reaching the drainage canals. As a result, the intraocular pressure rises very quickly, causing a painful attack in the eye. The eye may appear red. Treatment of angle-closure glaucoma usually involves either laser or conventional surgery to remove a small portion of the bunched-up outer edgeof the iris. Surgery helps unblock the drainage canals so that the extra fluid can drain.

**Other types of Glaucoma**

Most of the other types of glaucoma are variations

of open-angle or angle-closure types. Thesetypes can occur in one or both of your eyes.

**Secondary Glaucoma**

It can occur as the result of an eye injury, inflammation, tumor, in advanced cases of cataract or diabetes or by certain drugs such as steroids. This form of glaucomamay be mild or severe.

**Pigmentary Glaucoma**

Is a form of secondary open-angle glaucoma, occurring when the pigment granules that are in the back of the iris (the colored part of the eye) break into the clear fluid produced inside the eye. These tiny pigment granules flow toward the drainage canals in theeye and slowly clog them, causing eye pressure to rise. Treatment usually includes medications, laser surgery, or filtering surgery.

**Normal-tension Glaucoma (NTG)**

It is also called low-tension or normal-pressure glaucoma. In this type of glaucoma, the optic nerve is damaged even though the intraocular pressure is not very high. The cause is unknown. People at higher risk for normal tension glaucoma have a family history of normal-tension glaucoma, are of Japanese ancestry, or have a history of systemic heartdisease, such as irregular heart rhythm

**Congenital Glaucoma**

Occurs in babies when there’s incorrect or incomplete development of the eye’s drainage canals during the prenatal period. This is a rare condition that may be inherited. ExfoliativeGlaucoma occurs when a flaky, dandruff-like material peels off the outer layer of the lens within the eye. The material collects in the angle between the cornea and iris and can clog the drainage system of the eye, causing eye pressure to rise.

Congenital glaucoma can often be corrected with microsurgery.

**Neovascular Glaucoma-**

The abnormal formation of new blood vessels on the iris and overthe eye’s drainage channels can cause this form of open-angle glaucoma. Neovascular glaucoma is always associated with other abnormalities, most often diabetes. It never occurs on its own. The new blood vessels block the eye’s fluid from exiting through the trabecular meshwork (the eye’s drainage canals),causing an increase in eye pressure.

**Uveitic Glaucoma**

Uveitis is swelling and inflammation of the uvea, the middle layer of the eye. The uvea provides most of the blood supply to the retina. Increased eye pressure in uveitiscan result from the inflammatory process itself or the medication (steroids) used to treat it.

**Traumatic Glaucoma**

Injury to the eye may cause traumatic glaucoma. This form of open-angle glaucoma can occur immediately after the injury or develop years later. It can be caused by blunt injuries that bruise the eye (called blunt trauma) or by injuries that penetrate the eye.

**DIAGNOSIS 15, 16**

In less common kinds of glaucoma, symptoms can be more severe. Thesesymptoms can include:

• Hazy vision.

• The appearance of rainbow-colored circles around bright lights.

• Sudden sight loss.

• Eye and head pain

• Nausea or vomiting.

To be safe and accurate, following diagnostic

exams should be used for glaucoma diagnosis:

1. **Tonometry-** The inner eye pressure (IOP)

2. **Ophthalmoscopy or dilated eye exam-** The shape and color of the optic nerve.

3. **Perimetry test-** The complete field of vision.

4. **Gonioscopy-** The angle in the eye where the iris meets the cornea.

**5. Pachymetry-** Thickness of the cornea.

It is also important to interview the patient concerning subjective symptoms,with symptoms such as blurred vision, irisopsia, eye pain, headache, and hyperemia indicating a possible history of acute glaucoma attacks. Patient’s family history, and patients with a family history of glaucoma in particular should be asked about visual function damage in blood relatives.

**Treatment**

The purpose of glaucoma therapy at the present time is to maintain the patient’s visual function.

At present, based on the evidence, the only reliable treatment for glaucoma is to decrease IOP. Improvement of ocular blood flow and direct neuroprotection have attracted attention as new therapeutic methods involving factors other than IOP, and these maybecome innovative therapeutic options in the future.

* Medication
* Laser use and surgery

**1. Medication**

**i). Eye drops17, 18, 19, 20, 21**

Glaucoma treatment often starts with eye drops. These can helpdecrease eye pressure by improving fluid drains from eye. Prescription eye drop medications include-

**i. Prostaglandins.** These increase the outflow of the fluid in eye and reduce pressure.

**Examples-** latanoprost (Xalatan) and bimatoprost (Lumigan).

**Side effects-** mild reddening and stinging of the eyes, darkening of the iris, changes in the pigment of the eyelashes or eyelid skin, and blurred vision.

**ii. Beta blockers.** These reduce the production of fluid in eye, thereby lowering the pressure in eye.

**Examples**- timolol and betaxolol.

**Side effects-** difficulty breathing, slowed heart rate, lower blood pressure,impotence and fatigue.

**iii. Alpha-adrenergic agonists.** These reduce the production of aqueous humor and increase outflow of the fluid in eye.

 **Examples**- apraclonidine (Iopidine) and brimonidine (Alphagan).

**Side effects-** an irregular heart rate; high blood pressure; fatigue; red, itchy or swollen eyes; and dry mouth.

**iv. Carbonic anhydrase inhibitors.** Rarely used for glaucoma, these drugs may reduce the production of fluid in eye.

**Examples**- dorzolamide (Trusopt) and brinzolamide (Azopt).

**Side effects-** metallic taste, frequent urination, and tingling in the fingers and toes.

**v. Miotic or cholinergic agents.** These increase the outflow of fluid from eye.

 **Examples**- pilocarpine.

**Side effects-** smaller pupils, possible blurred or dim vision, and nearsightedness.

**Oral medications22**

If eyedrops alone don't bring eye pressure down to the desired level, usually a carbonic anhydrase inhibitors are prescribed as an oral medication. Possible side effects include frequent urination, tingling in the fingers and toes, depression, stomach upset, and kidney stones.

**Laser use and surgery23, 24, 25, 26**

Other treatment options include laser therapy and various surgical procedures. Possible complications include pain, redness, infection, inflammation, bleeding,abnormally high or low eye pressure, and loss of vision. Some types of eye surgery may speed the development of cataracts. Surgery is the main treatment method for angle-closure glaucoma and congenital glaucoma, because it may be the only way that the blocked or incorrectly formed drainage canals can be opened. In cases of open-angle glaucoma, surgery is usually considered when the maximum amount of medication is not controlling eye pressure or when patient cannot tolerate the side effects of the medication. The primary strategy involves “burning” holes in various areas within the eyes including the ciliary and the pigmented trabecular meshwork cells. The benefits include being noninvasive, needing less patient compliance andlowering the possibility of infection or bleeding.

**Types of laser surgery:**

**1. Argon Laser Trabeculoplasty (ALT)**

Used for primary open-angle glaucoma. Laser beam is aimed at the fluid drainage channels helping the drainage system work.

**2. Selective Laser Trabeculoplasty (SLT)**

Uses a laser that works at very low levels. Treats specific cells and leavesthe mesh-like drainage canals surrounding the iris intact. Because it affects only certain cells without causing collateral tissue damage, SLT can potentially be repeated.

**3. Laser Peripheral Iridotomy (LPI)**

LPI is frequently used to treat angle-closure

glaucoma, in which the angle between the iris and the cornea is toosmall and blocks fluid flow out of the eye. A laser creates a small hole in the iris to allow fluid drainage.

**4. Micropulse Laser Trabeculoplasty (MLT)**

Provides the same pressure-lowering effects as SLT and ALT. Uses a specific diode laser to deliver laser energy in short microbursts.

**5. Laser Cyclophotocoagulation**

This procedure is usually used to treat more aggressive or advanced open-angle glaucoma that has not responded to other therapies. Your doctor directs a laser through the sclera or endoscopically at the eye fluid-producing ciliary body. The procedurehelps decrease the production of fluid and lower eye pressure. Patients often need multiple treatments.

**Incisional surgery**

Incisional surgery is use in cases in which sufficient reduction of IOP cannot be achieved by other therapeutic means, or cases in which other appropriate means of treatment cannot be used because of adverse effects or non-compliance, and cases in which it isthought that sufficient reduction of IOP cannot be achieved by other therapeutic means.

The indication for surgery must be made for each individual patient based on a comprehensive assessment of type of glaucoma, stage of glaucoma, the patient’s disease awareness, compliance, and the patient’s social background.

**Conclusion-**

Glaucoma is significant public health challenge because it is irreversible. The therapies available for glaucoma can prevent or slow vision loss, but once vision has been lost it cannot be restored. Early diagnosis and treatment can prevent vision loss from the disease.

Treatment options for patients with glaucoma include medications,laser therapy, and incisional surgery. The risks and benefits of each type of treatment must be carefully considered to maximize the treatment’s benefits while minimizing adverse effects. There is need of advances in glaucoma treatment because proven medical and surgical therapies are limited in their capacity to stop glaucoma progression.

**References**

**1.** Choi J, Jeong J, Ho HS, Kook MS, Effect of nocturnal blood pressure reduction on circadian fluctuation of mean ocular perfusion pressure: a risk factor for normal tension glaucoma, Investigative Ophthalmology and Visual Science. 2006, 47(3), 831–836, 2006.

2. Song YK, Lee CK, Kim J, Hong S, Kim CY, Seong GJ, Instability of 24-hour intraocular pressure fluctuation in healthy young subjects: a prospective, cross-sectional study, BMC Ophthalmology. 2014, 127, 2014.

3. Scheer FAJL, Michelson AD, Frelinger AL. The human endogenous circadian system causes greatest platelet activation during the biological morning independent of behaviors, PLoS ONE. 2011, 6 (9), 245-49.

4. Cherecheanu AP, Garhofer G, Schmidl D, Werkmeister R, Schmetterer L, Ocular perfusion pressure and ocular blood flow in glaucoma, *Current Opinion in Pharmacology*. 2013, 13 (1), 36–42.

5. Schmidl D, Garhofer G, Schmetterer L, The complex interaction between ocular perfusion pressure and ocular blood flow- relevance for glaucoma, *Experimental Eye Research*. 2011, 93 (2), 141–155.

6. Gazzard G, Friedman DS, Devereux JG, Chew P, Seah SK. A prospective ultrasound biomicroscopy evaluation of changes in anterior segment morphology after laser iridotomy in Asian eyes. Ophthalmology. 2003, 110: 630–638.

7. Nolan WP, Foster PJ, Devereux JG, Uranchimeg D, Johnson GJ. YAG laser iridotomy treatment for primary angle closure in east Asian eyes. *Br J Ophthalmol*. 2000, 84: 1255-1259.

8. Weinreb RN, Toris CB, Gabelt BT, Lindsey JD, Kaufman PL. Effects of prostaglandins on the aqueous humor outflow pathways. Surv Ophthalmol. 2002; 47: S53–64.

9. Snyder RW, Stamer WD, Kramer TR, Seftor REB. Corticosteroid treatment and trabecular meshwork proteases in cell and organ culture supernatants. *Exp Eye Res.* 1993; 57:461–468.

10. Weinreb RN, Mitchell MD, Polansky JR. Prostaglandin production by human trabecular meshwork cells: in vitro inhibition by dexamethasone. *Invest Ophthalmol Vis Sci*. 1983; 24:1541–1545.

11. Chauhan MK., Yenamandra J. Management of glaucoma: effective drug delivery via niosomes, *Journal of Drug delivery and therapeutics*. 2016; 6(6):48-53.

12. Klink T, Praetorius S, Leippi S, Klink J, Grehn FJ. Diurnal and nocturnal intraocular pressure fluctuations after trabeculectomy. Ophthalmologica, 2012; 227:160-5.

13. Klink T, Praetorius S, Leippi S, Klink J, Grehn FJ. Diurnal and nocturnal intraocular pressure fl uctuations after trabeculectomy. Ophthalmologica. 2012; 227:160-5.

14. Woodward DF, Gil DW. The inflow and outflow of anti-glaucoma drugs. *Trends Pharmaco*l. Sci. 2004, 25:238.

15. Schwartz K. and D. Budenz. Current management of glaucoma. *Curr. Opin. Ophthalmol*. 2004, 15:119.

16. Osborne NN, Wood JP, Cupido A, Melena J, Chidlow G. Topical flunarizine reduces IOP and protects the retina against ischemia-excitotoxicity. Invest. *Ophthalmol. Vis. Sci*. 2002, 43:1456.

17. Chong ZZ, SH Lin, JQ Kang, K. Maiese. Erythropoietin prevents early and late neuronal demise through modulation of Akt1 and induction of caspase 1, 3 and 8. *J. Neurosci*. 2003, Res. 71:659.

****

**Eye drops for treatment of Glaucoma**